- Home
- HUYA vs AKBA Comparison
HUYA vs AKBA Comparison
Compare HUYA & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUYA
- AKBA
- Stock Information
- Founded
- HUYA 2014
- AKBA 2007
- Country
- HUYA China
- AKBA United States
- Employees
- HUYA N/A
- AKBA N/A
- Industry
- HUYA Computer Software: Programming Data Processing
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- HUYA Technology
- AKBA Health Care
- Exchange
- HUYA Nasdaq
- AKBA Nasdaq
- Market Cap
- HUYA 713.8M
- AKBA 729.1M
- IPO Year
- HUYA 2018
- AKBA 2014
- Fundamental
- Price
- HUYA $3.04
- AKBA $3.03
- Analyst Decision
- HUYA Buy
- AKBA Strong Buy
- Analyst Count
- HUYA 2
- AKBA 5
- Target Price
- HUYA $4.50
- AKBA $6.90
- AVG Volume (30 Days)
- HUYA 920.8K
- AKBA 2.6M
- Earning Date
- HUYA 11-12-2025
- AKBA 11-06-2025
- Dividend Yield
- HUYA 81.64%
- AKBA N/A
- EPS Growth
- HUYA N/A
- AKBA N/A
- EPS
- HUYA N/A
- AKBA N/A
- Revenue
- HUYA $852,782,043.00
- AKBA $203,733,000.00
- Revenue This Year
- HUYA $8.16
- AKBA $43.91
- Revenue Next Year
- HUYA $5.11
- AKBA $32.09
- P/E Ratio
- HUYA N/A
- AKBA N/A
- Revenue Growth
- HUYA N/A
- AKBA 16.75
- 52 Week Low
- HUYA $2.21
- AKBA $1.52
- 52 Week High
- HUYA $4.59
- AKBA $4.08
- Technical
- Relative Strength Index (RSI)
- HUYA 41.30
- AKBA 55.00
- Support Level
- HUYA $2.85
- AKBA $2.93
- Resistance Level
- HUYA $3.13
- AKBA $3.18
- Average True Range (ATR)
- HUYA 0.09
- AKBA 0.14
- MACD
- HUYA 0.00
- AKBA 0.03
- Stochastic Oscillator
- HUYA 44.88
- AKBA 68.37
About HUYA HUYA Inc. American depositary shares each representing one ordinary share
Huya, officially became independent in 2016 and headquartered in Guangzhou, operates live streaming platform focused on games, esports, and interactive entertainment, and also provides game-related services such as distribution and in-game item sales. Its main livestreaming platforms include Huya Live in China and Nimo TV outside of China. As of 2024, Huya was a subsidiary of Tencent, which owned 67% of its equity stake and held 95% of the voting power.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.